Autosomal Dominant

Definition and Overview

Basic Concept

Autosomal dominant inheritance: phenotype expressed when at least one dominant allele present on autosomal chromosome pair. Trait or disorder manifests in heterozygous or homozygous dominant states.

Chromosomal Location

Occurs on autosomes: chromosomes 1-22, excluding sex chromosomes X and Y. Equal transmission probability from either parent to offspring.

Clinical Relevance

Common in single-gene disorders with dominant mutations. Enables prediction of trait transmission in families. Important for diagnosis and management of hereditary diseases.

"In autosomal dominant inheritance, one copy of a mutant gene is sufficient to cause a phenotype." -- Strachan & Read, Human Molecular Genetics

Genetic Mechanism

Dominant Allele Function

Dominant allele encodes functional or altered protein affecting phenotype. Wild-type allele may be suppressed or insufficient to mask mutant effect.

Haploinsufficiency

One functional allele insufficient for normal phenotype. Result: disease manifests despite presence of one normal allele.

Gain-of-Function Mutations

Mutant protein gains abnormal function, causing dominant phenotypic effect. Examples include constitutive enzyme activation or toxic protein aggregation.

Dominant-Negative Effect

Mutant protein interferes with normal protein function, reducing overall activity despite presence of wild-type allele.

Inheritance Pattern

Transmission Probability

Each child has 50% chance inheriting dominant mutant allele from affected parent. Independent of sex of parent and offspring.

Vertical Transmission

Trait appears in every generation unless penetrance incomplete. Affected individuals usually have affected parent.

Sex Distribution

Both males and females equally affected and transmit equally. No sex linkage involved.

New Mutations

Occasional spontaneous mutations cause autosomal dominant traits without family history. Important in genetic counseling.

Molecular Basis

Types of Mutations

Point mutations: missense, nonsense. Insertions/deletions causing frameshifts. Copy number variations.

Protein Impact

Altered protein stability, conformation, interaction, or enzymatic activity. May affect signaling pathways, structural components, or regulatory factors.

Gene Examples

COL1A1 (osteogenesis imperfecta), FGFR3 (achondroplasia), HTT (Huntington disease).

Allelic Heterogeneity

Different mutations in same gene produce similar or variable phenotypes with autosomal dominant inheritance.

Penetrance and Expressivity

Penetrance

Probability that a genotype manifests as phenotype. Complete penetrance: 100% expression. Incomplete penetrance: some carriers asymptomatic.

Expressivity

Degree to which phenotype is expressed among individuals with same genotype. Can vary in severity, age of onset, symptoms.

Modifier Genes

Other genetic factors influence penetrance and expressivity, modifying clinical outcomes.

Environmental Influence

External factors can impact phenotype expression, complicating inheritance predictions.

Pedigree Analysis

Pattern Recognition

Vertical inheritance pattern with affected individuals in multiple generations. 50% offspring risk from affected parent.

Symbol Conventions

Squares: males; circles: females; shaded: affected; unshaded: unaffected. Half-shaded or other notations for carriers or unknown status.

Distinguishing from Other Patterns

No sex bias unlike X-linked. No skipping of generations unless incomplete penetrance. Differentiates from autosomal recessive and mitochondrial.

Example Pedigree Table

Clinical Examples

Huntington Disease

Neurodegenerative disorder caused by CAG repeat expansion in HTT gene. Adult onset, progressive motor dysfunction, cognitive decline.

Achondroplasia

Dwarfism caused by FGFR3 gene mutation. Short limbs, normal intelligence. Most cases sporadic new mutations.

Marfan Syndrome

Connective tissue disorder due to FBN1 gene mutations. Cardiovascular, skeletal, ocular abnormalities.

Osteogenesis Imperfecta

Brittle bone disease from COL1A1 or COL1A2 mutations. Variable severity, blue sclerae, dentinogenesis imperfecta.

Neurofibromatosis Type 1

Mutation in NF1 gene. Tumors of nerve sheath, café-au-lait spots, skeletal dysplasias.

Diagnosis and Genetic Testing

Clinical Criteria

Based on family history, characteristic phenotypes, physical examination. Early diagnosis critical for management.

Molecular Testing

DNA sequencing to detect pathogenic variants. Targeted mutation analysis or whole exome/genome sequencing.

Biochemical Tests

Protein assays, enzyme activity measurements if applicable.

Preimplantation and Prenatal Testing

Available for families with known mutations. Enables informed reproductive choices.

Genetic Counseling

Risk Assessment

Determination of offspring risk (usually 50%) based on parental genotype. Consideration of penetrance and expressivity.

Family Planning

Options include prenatal diagnosis, assisted reproduction, adoption. Discussion of ethical and psychosocial factors.

Psychosocial Support

Address anxiety, stigma, implications of late-onset diseases. Provide resources and referrals.

Communication Strategies

Clear explanation of inheritance mode, recurrence risk, and testing options.

Population Genetics

Allele Frequency

Dominant alleles usually rare due to negative selection if disease-causing. Some common due to founder effects or heterozygote advantage.

Mutation Rate

New mutations contribute to disease prevalence. Rates vary by gene and locus.

Founder Effects

Certain populations show higher prevalence due to limited genetic diversity and ancestral mutations.

Genetic Drift and Selection

Influence allele frequencies over generations. Dominant deleterious alleles often selected against.

Therapeutic Implications

Targeted Therapies

Gene editing (CRISPR), antisense oligonucleotides, small molecules targeting mutant proteins.

Symptomatic Treatment

Management of clinical manifestations such as pain, mobility, organ function.

Preventive Strategies

Surveillance for complications, lifestyle modification, early intervention.

Research Directions

Focus on molecular pathogenesis to develop novel therapeutics.

Recent Advances

Next-Generation Sequencing

Improved detection of causative mutations, identification of novel variants.

Functional Genomics

CRISPR screens, transcriptomics reveal gene networks and modifier loci.

Gene Therapy Trials

Emerging trials targeting dominant negative mutations with allele-specific silencing.

Personalized Medicine

Integration of genomic data for individualized risk prediction and treatment.

Inheritance_Risk = 0.5 × PenetranceExpressivity = Variable; influenced by genetic modifiers + environmentDisease_Severity ∝ Mutation_Type + Allelic_Context + Modifier_Genes

References

• Strachan T, Read AP. Human Molecular Genetics. 4th ed. Garland Science; 2010.
• Griffiths AJF, Wessler SR, Carroll SB, Doebley J. Introduction to Genetic Analysis. 11th ed. W. H. Freeman; 2015.
• Cooper DN, Krawczak M. The mutational spectrum of single base-pair substitutions causing human genetic disease: patterns and predictions. Hum Genet. 1990;85(1):55-74.
• Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11(5):863-874.
• Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10(9):531-547.